Erythema Discromicum Perstans Related with Oral Contraceptive and Progesterone Injections

  • Gonca Soyuduru
  • Esra Adışen Gazi ÜTF Dermatoloji AD
  • Mehmet Ali Gürer
Keywords: Erythema discromicum perstans, oral contraceptives, progesterone

Abstract

Erythema discromicum perstans is clinically characterized by asymptomatic, hyperpigmented macules  of various size on the face, trunk and extremities. It typically occurs in the second decade of life and generally affects those with phototype IV skin. The etiology of erythema discromicum perstans is unknown but associations with endocrinopathies, infestations, infections, and  drug allergies have been reported. The association with oral contraceptives and progesterone injections has not been reported yet in the literature.  Herein, we report a case of a 34 year old woman who presented  with  extensive and progressive erythema discromicum perstans induced and/or exacerbated by the ingestion of oral contraceptives and multiple  progesterone injections. We aim to emphasize the “probable” side effect of these drugs. Awareness of this probable association  deserves attention due to the widespread use of  oral contraceptive pills and/or  progesterone injections.

References

Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol 2004; 43: 230-2.

Goihman-Yahr M. Letter: Erythema dyschromicum perstans revisited. Dermatol Online J 2011; 17: 14.

Vásquez-Ochoa LA, Isaza-Guzmán DM, Orozco-Mora B, Restrepo-Molina R, Trujillo-Perez J, Tapia FJ. Immunopathologic study of erythema dyschromicum perstans (ashy dermatosis). Int J Dermatol 2006; 45: 937-41.

Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol 2005; 19: 422-6.

Persechino S, Caperchi C, Cortesi G, Persechino F, Raffa S, Pulcini F, Tammaro A, Torrisi MR. Erythema dyschromicum perstans in phototype II women: three unusual clinical cases studied with electron microscopy. Eur J Dermatol 2011; 21: 261-2.

Bahadir S, Cobanoglu U, Cimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol 2004; 43: 220-2.

Baranda L, Torres-Alvarez B, Cortes-Franco R, Moncada B, Portales-Perez DP, Gonzalez-Amaro R. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Arch Dermatol 1997; 133: 325-9.

Penagos H, Jimenez V, Fallas V, O'Malley M, Maibach HI. Chlorothalonil, a possible cause of erythema dyschromicum perstans (ashy dermatitis). Contact Dermatitis 1996; 35: 214-8.

Chua S, Fung MC, Lee HY. Ashy dermatosis (erythema dyschromicum perstans) induced by omeprazole: a report of three cases. Int J Dermatol 2015 Jul 3. doi: 10.1111/ijd.12844.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.

Published
2016-01-10